News | August 26, 2025
Merck presents new data on cardiovascular disease at ESC Congress 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Inclacumab was generally well tolerated in THRIVE-131
Phase 1 dosing is expected to finish by the end of 2025
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Subscribe To Our Newsletter & Stay Updated
